Home Chemicals & Materials Industrial Gases Inhaled Nitric Oxide Market

Inhaled Nitric Oxide Market Size, Share & Trends Analysis Report By Application (Neonatal respiratory treatment, Chronic obstructive pulmonary disease (COPD), Acute respiratory distress syndrome (ARDS)) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Anantika Sharma | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Inhaled Nitric Oxide Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Neonatal respiratory treatment
    2. Chronic obstructive pulmonary disease (COPD)
    3. Acute respiratory distress syndrome (ARDS)
  2. Regional Inhaled Nitric Oxide Market
    1. North America
      1. North America Inhaled Nitric Oxide Market By Application 2022-2034 (USD MILLION/ Units)
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      2. U.S.
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      3. Canada
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
    2. Europe
      1. Europe Inhaled Nitric Oxide Market By Application 2022-2034 (USD MILLION/ Units)
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      2. U.K.
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      3. Germany
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      4. France
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      5. Spain
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      6. Italy
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      7. Russia
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      8. Nordic
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      9. Benelux
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      10. Rest of Europe
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
    3. APAC
      1. APAC Inhaled Nitric Oxide Market By Application 2022-2034 (USD MILLION/ Units)
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      2. China
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      3. Korea
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      4. Japan
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      5. India
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      6. Australia
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      7. Taiwan
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      8. South East Asia
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      9. Rest of Asia-Pacific
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
    4. Middle East and Africa
      1. Middle East and Africa Inhaled Nitric Oxide Market By Application 2022-2034 (USD MILLION/ Units)
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      2. UAE
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      3. Turkey
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      4. Saudi Arabia
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      5. South Africa
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      6. Egypt
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      7. Nigeria
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      8. Rest of MEA
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
    5. LATAM
      1. LATAM Inhaled Nitric Oxide Market By Application 2022-2034 (USD MILLION/ Units)
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      2. Brazil
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      3. Mexico
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      4. Argentina
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      5. Chile
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      6. Colombia
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
      7. Rest of LATAM
        1. Neonatal respiratory treatment
        2. Chronic obstructive pulmonary disease (COPD)
        3. Acute respiratory distress syndrome (ARDS)
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.